EN
Sinovac Reports First Quarter 2008 Unaudited Financial Results
Sinovac Reports First Quarter 2008 Unaudited Financial Results
Friday May 16, 8:00 am ET
First Quarter Highlights -- Sales increased 123% year-over-year to $8.9 million -- Sold 1.5 million doses of Healive®, up 113% -- Gross profit grew 135% year-over-year to $7.8 million, with 88% gross margin -- Operating income rose 116% year-over-year to $3.1 million -- Net income increased to $1.6 million -- Diluted EPS grew 100% to $0.04 -- Completed $9.75 million private placement
Mr. Weidong Yin, Chairman, President and CEO, commented, "Our first quarter sales demonstrate the continued execution of our commercialization strategy. We were pleased with the 123% increase in quarterly sales. We continue to experience robust Healive® sales due to favorable market development trends in China."
Mr. Yin continued, "We are pleased with the continued clinical advancement of our pandemic influenza vaccine formulations. In early April, we received a production license from the SFDA to exclusively supply Panflu(TM), our whole viron H5N1 pandemic influenza vaccine, to the national stockpiling program. Recently, we successfully completed Phase I trials for the split vaccine and intend to commence the Phase II trials during the second quarter of 2008."
Three Months Ended March 31, 2008
For the first quarter 2008, sales increased 123% to $8.9 million, compared to $4.0 million in the first quarter 2007. The growth was driven by higher sales of Healive® with further market.
Gross profit for first quarter of 2008 was $7.8 million, with a gross margin of 88.2%, compared to $3.3 million and 83.9%, respectively, for the same period of 2007. The higher gross margin resulted from the increased economies of scale and lower average unit costs associated with Healive® production.
Total operating expenses for the first quarter of 2008 increased to $4.7 million, compared to $1.9 million in the same period of 2007. Selling, general and administrative expenses for first quarter of 2008 were $3.6 million, compared to $1.3 million in the same period of 2007. The year-over-year increase in SG&A expenses reflected Sinovac's extensive promotion campaign for Healive®, and the recruiting of additional employees for the production, quality control, sales, and marketing segments to position the Company for market growth.
The aggregated research and development expenses for the first quarter of 2008 were $933,000 compared to $477,000 in the same period of 2007. Our net R&D expenses were $929,000 for the first quarter of 2008, compared to $444,000 in the same period of 2007. The R&D expenses recognized as a reduction to government grants were $4,000 in the first quarter of 2008, compared to $33,000 in the same period of 2007.
Operating income was $3.1 million for the first quarter of 2008, compared to $1.5 million in the same period of 2007. The year-over-year increase in operating income reflected the significant increase in vaccine sales and the moderately higher operating expenses.
Net income for the first quarter of 2008 was $1.6 million, or $0.04 per diluted share, compared to $776,000, or $0.02 per diluted share, in the same period of 2007. Net income for the first quarter of 2008 included $158,000 of interest and financing expenses, $719,000 of income taxes, and $739,000 of minority interest. Net income for the same period of 2007 included $86,000 of interest and financing expenses, $342,000 of income taxes, and $310,000 of minority interest.
As of March 31, 2008, Sinovac's cash and cash equivalents totaled $20.6 million, compared to $17.1 million as of December 31, 2007.
Sales and Marketing
During the first quarter of 2008, Sinovac sold approximately 1.5 million doses of Healive®, up from 0.7 million doses for the same period of 2007. Higher sales in the first quarter of 2008 resulted from Healive promotion campaign targeting the private market. During the first quarter of 2008, Sinovac sold 31,000 doses of Bilive® and 24,000 doses seasonal flu vaccine.
Research and Development
In April 2008, Sinovac was granted a production license for Panflu(TM) by the China State Food and Drug Administration (SFDA). PanfluTM is the first and only approved vaccine available in China against the H5N1 influenza virus. Under the production license for Panflu(TM) granted by SFDA, the vaccine is solely approved for production to be supplied to the Chinese national vaccine stockpiling program and will not be sold directly to the market.
Sinovac has successfully completed the Phase I clinical trials for its split pandemic influenza vaccine.
The Phase I trial for the split pandemic influenza vaccine was conducted by the Beijing Centers for Disease Control and Prevention, located in Huai Rou, Beijing. The trial enrolled 160 volunteers from 3 to 70 years old, sorted into four different age groups, who received doses of 5ug, 10ug, 15ug or 30ug and were followed for an observation period. There were no serious adverse events.
Sinovac is on track to commence a Phase II trial of the split pandemic influenza vaccine in the second quarter of 2008. The trial will include 350 volunteers covering three different age groups, namely children, adults and elderly, to further assess the immunogenicity and safety of the vaccine as well as determine vaccination dosage.
Conference Call Details
The Company will host a conference call on Friday, May 16, 2008 at 9:00 a.m. ET (9:00 p.m. Beijing time). To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00 a.m. ET on May 16, until May 30, 2008 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 285507. A live audio webcast of the call will also be available from the Investors section on the corporate web site at http://www.sinovac.com . A webcast replay can be accessed on the corporate website beginning May 16, 2008 and the replay will remain available for 30 days.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing universal pandemic influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
SINOVAC BIOTECH LTD. Consolidated Statements of Income and Comprehensive Income Three Months Ended March 31, 2008 and 2007 (Unaudited) (Expressed in U.S. Dollars) 2008 2007 Sales $8,862,001 $3,973,052 Cost of sales - (exclusive of depreciation of land-use rights and amortization of licenses and permits of $99,834 (2007 - $92,728) 1,047,866 641,450 Gross profit 7,814,135 3,331,602 Selling, general and administrative expenses 3,577,886 1,268,544 Research and development expenses - net of $4,019 (2007 - $33,175) in government research grants 929,336 443,745 Depreciation of property, plant and equipment and amortization of licenses and permits 178,229 169,041 Total operating expenses 4,685,451 1,881,330 Operating income 3,128,684 1,450,272 Interest and financing expenses (157,707) (86,056) Interest and other income 46,350 64,024 Income before income taxes and minority interest 3,017,327 1,428,240 Income tax expenses - Current 645,335 290,219 - Deferred 73,181 51,735 Income before minority interest 2,298,811 1,086,286 Minority interest share of income 738,855 309,915 Net income for the period $1,559,956 $776,371 Other comprehensive income Cumulative translation adjustment $1,282,528 $180,423 Comprehensive income $2,842,484 $956,794 Earnings per share - basic and diluted $0.04 $0.02 Weighted average number of shares of Common stock outstanding - Basic 41,088,322 40,199,948 - Diluted 41,470,579 40,524,360 SINOVAC BIOTECH LTD. Consolidated Balance Sheets (Unaudited) (Expressed in U.S. Dollars) March 31, 2008 December 31, 2007 ASSETS Current assets Cash and cash equivalents $20,578,712 $17,071,497 Accounts receivable - net 21,289,266 16,983,892 Inventories 5,382,776 3,745,957 Prepaid expenses and deposits 566,869 800,840 Deferred tax assets 605,817 579,703 Total current assets 48,423,440 39,181,889 Restricted cash 1,401,510 846 Property, plant and equipment 17,474,369 15,879,391 Long-term prepaid expenses and deposits 248,697 298,731 Deferred tax asset 593,757 693,053 Licenses and permits 1,355,097 1,394,052 Total assets $69,496,870 $57,447,962 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Loans payable $7,120,276 $6,836,110 Accounts payable and accrued liabilities 10,528,253 9,522,818 Due to related parties 46,971 46,971 Dividends payable to minority interest of Sinovac Beijing 112,909 3,000,458 Deferred research grants 1,077,452 1,038,396 Total current liabilities 18,885,861 20,447,754 Deferred government grants 2,848,110 2,734,444 Loan Payable 1,424,055 1,367,222 Long - term debt 4,272,165 4,101,666 Total liabilities 23,158,026 24,546,420 Minority interest 3,662,570 2,897,687 Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock -- -- Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil Common stock 42,813 40,305 Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 42,813,028 (2007 - 40,305,028 ) Subscriptions received 61,990 9,170 Additional paid in capital 41,884,604 32,109,997 Accumulated other comprehensive income 3,238,984 1,956,456 Dedicated reserves 2,999,396 2,999,396 Accumulated deficit (5,551,513) (7,111,469) Total stockholders' equity 42,676,274 30,003,855 Total liabilities and stockholders' equity $69,496,870 $ $57,447,962 For more information, please contact: Contact Information: Investors/Media: Helen G. Yang Stephanie Carrington/Janine McCargo Sinovac Biotech Ltd. The Ruth Group Tel: +86-10-8289-0088 x871 Tel: +1-646-536-7017/7033 Fax: +86-10-6296-6910 Email: scarrington@theruthgroup.com Email: info@sinovac.com jmccargo@theruthgroup.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com